IDEAS home Printed from https://ideas.repec.org/a/wly/hlthec/v11y2002i7p637-647.html
   My bibliography  Save this article

Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?

Author

Listed:
  • Joanna Coast
  • Richard Smith
  • Anne‐Marie Karcher
  • Paula Wilton
  • Michael Millar

Abstract

To date, there has been little examination of the problems associated with conducting economic evaluation for interventions designed to contain antimicrobial resistance. There are two quite different types of intervention aimed at containing antimicrobial resistance: interventions which are designed to avoid the emergence of resistant organisms; and interventions that are designed to avoid the transmission of resistance organisms. Four aspects of economic evaluation where the ease of assessment might be expected to differ across evaluations for these different types of intervention are examined: problems associated with the identification of diffuse impacts, problems associated with comparing current and future impacts, problems associated with uncertainty, and problems associated with difficulties in measurement and valuation. The paper suggests that it may be much easier to conduct rigorous economic evaluations for interventions designed to avoid transmission of resistance, than for those intended to avoid emergence. Unfortunately, the transmission policies, which are likely to be the easiest to evaluate, are not likely to produce an optimal long‐term outcome given the apparent irreversability of much resistance and the potentially severe harms which could be imposed as a result. Given the desirability of avoiding a scenario where, in the evidence‐based medicine culture, the most rigorously evaluated policies are followed even though they may be less important, there is the need to consider carefully what, and how, economic evaluation should be conducted in the area of antimicrobial resistance. It is suggested that research should focus on the use of modelling as a means of evaluating optimal policy responses and on trying to resolve some of the difficulties associated with measurement and valuation. Copyright © 2002 John Wiley & Sons, Ltd.

Suggested Citation

  • Joanna Coast & Richard Smith & Anne‐Marie Karcher & Paula Wilton & Michael Millar, 2002. "Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?," Health Economics, John Wiley & Sons, Ltd., vol. 11(7), pages 637-647, October.
  • Handle: RePEc:wly:hlthec:v:11:y:2002:i:7:p:637-647
    DOI: 10.1002/hec.693
    as

    Download full text from publisher

    File URL: https://doi.org/10.1002/hec.693
    Download Restriction: no

    File URL: https://libkey.io/10.1002/hec.693?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Brown, Gardner & Layton, David F., 1996. "Resistance economics: social cost and the evolution of antibiotic resistance," Environment and Development Economics, Cambridge University Press, vol. 1(3), pages 349-355, July.
    2. Coast, J. & Smith, R. D. & Millar, M. R., 1998. "An economic perspective on policy to reduce antimicrobial resistance," Social Science & Medicine, Elsevier, vol. 46(1), pages 29-38, January.
    3. Smith, Richard D. & Coast, Joanna, 1998. "Controlling antimicrobial resistance: a proposed transferable permit market," Health Policy, Elsevier, vol. 43(3), pages 219-232, March.
    4. Joanna Coast & Richard D. Smith & Michael R. Millar, 1996. "Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation?," Health Economics, John Wiley & Sons, Ltd., vol. 5(3), pages 217-226, May.
    5. Kenneth J. Arrow & Anthony C. Fisher, 1974. "Environmental Preservation, Uncertainty, and Irreversibility," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 88(2), pages 312-319.
    6. Burton A. Weisbrod, 1964. "Collective-Consumption Services of Individual-Consumption Goods," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 78(3), pages 471-477.
    7. Sugden, Robert & Williams, Alan, 1978. "The Principles of Practical Cost-Benefit Analysis," OUP Catalogue, Oxford University Press, number 9780198770411, Decembrie.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. David H. Howard, 2004. "Resistance‐induced antibiotic substitution," Health Economics, John Wiley & Sons, Ltd., vol. 13(6), pages 585-595, June.
    2. Lucy Abel & Bethany Shinkins & Alison Smith & Andrew J. Sutton & Gurdeep S. Sagoo & Ijeoma Uchegbu & A. Joy Allen & Sara Graziadio & Eoin Moloney & Yaling Yang & Peter Hall, 2019. "Early Economic Evaluation of Diagnostic Technologies: Experiences of the NIHR Diagnostic Evidence Co-operatives," Medical Decision Making, , vol. 39(7), pages 857-866, October.
    3. Yoel Lubell & Thomas Althaus & Stuart D Blacksell & Daniel H Paris & Mayfong Mayxay & Wirichada Pan-Ngum & Lisa J White & Nicholas P J Day & Paul N Newton, 2016. "Modelling the Impact and Cost-Effectiveness of Biomarker Tests as Compared with Pathogen-Specific Diagnostics in the Management of Undifferentiated Fever in Remote Tropical Settings," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-13, March.
    4. Barlow, Euan & Morton, Alec & Megiddo, Itamar & Colson, Abigail, 2022. "Optimal subscription models to pay for antibiotics," Social Science & Medicine, Elsevier, vol. 298(C).
    5. Xuemei Zhen & Cecilia Stålsby Lundborg & Xueshan Sun & Xiaoqian Hu & Hengjin Dong, 2020. "Clinical and Economic Impact of Third-Generation Cephalosporin-Resistant Infection or Colonization Caused by Escherichia coli and Klebsiella pneumoniae : A Multicenter Study in China," IJERPH, MDPI, vol. 17(24), pages 1-12, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. John B. Horowitz & H. Brian Moehring, 2004. "How property rights and patents affect antibiotic resistance," Health Economics, John Wiley & Sons, Ltd., vol. 13(6), pages 575-583, June.
    2. Farasat A.S. Bokhari & Franco Mariuzzo & Weijie Yan, 2019. "Antibacterial resistance and the cost of affecting demand: the case of UK antibiotics," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2019-03, Centre for Competition Policy, University of East Anglia, Norwich, UK..
    3. Eswaran, Mukesh & Gallini, Nancy, 2016. "Rescuing the Golden Age of Antibiotics: Can Economics Help Avert the Looming Crisis?," Economics working papers nancy_gallini-2016-9, Vancouver School of Economics, revised 04 Jul 2016.
    4. Jackie Krafft & Isabelle Nicolaï, 1995. "Commitment Procedures In R&D Investments : An Examination Of Different Varieties," Post-Print hal-01799270, HAL.
    5. Belay, Dagim G. & Jensen, Jørgen D., 2020. "‘The scarlet letters’: Information disclosure and self-regulation: Evidence from antibiotic use in Denmark," Journal of Environmental Economics and Management, Elsevier, vol. 104(C).
    6. Gérard Mondello, 2012. "Ambiguity, Agency Relationships and Adverse Selection," Post-Print halshs-00929978, HAL.
    7. van den Bergh, Jeroen C.J.M., 2008. "Optimal diversity: Increasing returns versus recombinant innovation," Journal of Economic Behavior & Organization, Elsevier, vol. 68(3-4), pages 565-580, December.
    8. Smith, Richard D. & Yago, Milton & Millar, Michael & Coast, Jo, 2005. "Assessing the macroeconomic impact of a healthcare problem: The application of computable general equilibrium analysis to antimicrobial resistance," Journal of Health Economics, Elsevier, vol. 24(6), pages 1055-1075, November.
    9. Coggins, Jay S. & Ramezani, Cyrus A., 1998. "An Arbitrage-Free Approach to Quasi-Option Value," Journal of Environmental Economics and Management, Elsevier, vol. 35(2), pages 103-125, March.
    10. Gordon C. Rausser & Arthur A. Small, 2000. "Valuing Research Leads: Bioprospecting and the Conservation of Genetic Resources," Journal of Political Economy, University of Chicago Press, vol. 108(1), pages 173-206, February.
    11. Jinhua Zhao & Catherine L. Kling, 2009. "Welfare Measures when Agents can Learn: A Unifying Theory," Economic Journal, Royal Economic Society, vol. 119(540), pages 1560-1585, October.
    12. James R. Kahn & Robert V. O'Neill, 1999. "Ecological Interaction as a Source of Economic Irreversibility," Southern Economic Journal, John Wiley & Sons, vol. 66(2), pages 391-402, October.
    13. Miao, Ruiqing, 2012. "Essays on Investments in New Technologies --- Policy, Information, and Learning," ISU General Staff Papers 201201010800003414, Iowa State University, Department of Economics.
    14. Chichilnisky, Graciela, 1998. "The economics of global environmental risk," MPRA Paper 8812, University Library of Munich, Germany.
    15. Catherine Chambers & Paul Chambers & John Whitehead, 1997. "Historical resources, uncertainty and preservation values: An application of option and optimal stopping models," Journal of Economics and Finance, Springer;Academy of Economics and Finance, vol. 21(2), pages 51-61, June.
    16. Barlow, Euan & Morton, Alec & Megiddo, Itamar & Colson, Abigail, 2022. "Optimal subscription models to pay for antibiotics," Social Science & Medicine, Elsevier, vol. 298(C).
    17. Langholz, Jeffrey A. & Lassoie, James P. & Lee, David & Chapman, Duane, 2000. "Economic considerations of privately owned parks," Ecological Economics, Elsevier, vol. 33(2), pages 173-183, May.
    18. Catherine A. Goodman & Paul G. Coleman & Anne J. Mills, 2001. "Changing the first line drug for malaria treatment—cost‐effectiveness analysis with highly uncertain inter‐temporal trade‐offs," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 731-749, December.
    19. Perrings C., 1994. "Sustainable livelihoods and environmentally sound technology," ILO Working Papers 993004733402676, International Labour Organization.
    20. Elamin H. Elbasha, 2003. "Deadweight loss of bacterial resistance due to overtreatment," Health Economics, John Wiley & Sons, Ltd., vol. 12(2), pages 125-138, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:hlthec:v:11:y:2002:i:7:p:637-647. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/5749 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.